crizanlizumab-tmca (Adakveo)

Monoclonal antibody

Also known as SEG101

Approvedregulatory verdict

Evidence outlook

Approved: Sickle Cell Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Sickle Cell Disease
Phase 2 (7)
Sickle Cell Disease
NCT03474965 · Novartis Pharmaceuticals
2018-10-01 – 2024-11-06 · Sickle Cell Disease (SCD)
What this study did
NCT03938454 · Novartis Pharmaceuticals
2019-10-16 – 2023-11-29 · Priapism
What this study did
NCT03264989 · Novartis Pharmaceuticals
2017-12-19 – 2023-06-26 · Sickle Cell Disease (SCD)
What this study did
NCT04053764 · Novartis Pharmaceuticals
2019-12-10 – 2023-03-20 · Sickle Cell Disease (SCD)
What this study did
Other / comorbidity
NCT05909618 · Sheba Medical Center
2023-07-11 – 2030-07-30 · Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated Glioblastoma
What this study did
NCT04611880 · Washington University School of Medicine
2021-01-25 – 2025-12-31 · RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
What this study did
NCT04435184 · Johns Hopkins University
2020-07-09 – 2021-01-04 · COVID-19
What this study did
Phase 1/2 (2)
Sickle Cell Disease
NCT05469828 · Children's Hospital Los Angeles
2024-07-01 – 2029-07-01 · Sickle Cell Disease
What this study did
Other / comorbidity
NCT04097821 · Novartis Pharmaceuticals
2019-09-26 – 2024-08-28 · Myelofibrosis
What this study did
Phase 4 (3)
Sickle Cell Disease
NCT04657822 · Novartis Pharmaceuticals
2021-06-10 – 2031-06-10 · Sickle Cell Disease
What this study did
NCT04662931 · Novartis Pharmaceuticals
2021-07-14 – 2024-02-14 · Sickle Cell Disease (SCD)
What this study did
Other / comorbidity
NCT04505774 · Matthew Neal MD
2020-09-04 – 2024-01-26 · Covid19
What this study did
Early phase / not applicable (1)
Sickle Cell Disease
NCT05334576 · Andria Ford
2022-08-01 – 2025-07-01 · Sickle Cell Disease
What this study did

Competitive landscape

This drug's own stage for Sickle Cell Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Crizanlizumab-Tmca (Adakveo): this drugApprovedMonoclonal antibodyP-selectinPartial signalFeatured results are non-efficacy only in this race
Exagamglogene Autotemcel (Casgevy)ApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)Weak signalNo reviewed efficacy summary in this indication
Hydroxyurea (Droxia)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Siklos)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Xromi)ApprovedSmall moleculeRibonucleotide reductaseWeak signalNo reviewed efficacy summary in this indication
L-Glutamine (Endari)ApprovedSmall moleculeAmino AcidReliable signal
NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15)
Lovotibeglogene Autotemcel (Lyfgenia)ApprovedGene therapy / editingBeta-globin gene addition (betaA-T87Q)not yet gradedNo reviewed efficacy summary in this indication
EtavopivatPhase 3—Pyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Mitapivat (Pyrukynd)Phase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Decitabine / Tetrahydrouridine (NDec)Phase 2Small moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
ITU512Phase 1/2Small moleculeWIZ transcription factornot yet gradedNo reviewed efficacy summary in this indication
Nula-CelPhase 1/2Gene or cell therapy (subtype unspecified)HBB gene (sickle mutation correction)not yet gradedNo reviewed efficacy summary in this indication
Ristoglogene AutogetemcelPhase 1/2Gene therapy / editingHBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
DISC-3405Phase 1Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication
SCD-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
VAS-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)Reliable signal
NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92

Upcoming events

(4 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow crizanlizumab-tmca (Adakveo) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (2)
July 2028 (2)
Phase 1/2Sickle Cell DiseaseNot yet recruiting
Est. primary completion 2028-07-01 · NCT05469828 · CT.gov ↗
What to watch
Phase 2Advanced Glioblastoma, Metastatic Melanoma in the Central Nervous System, MGMT-Unmethylated GlioblastomaRecruiting
Est. primary completion 2028-07-30 · NCT05909618 · CT.gov ↗
What to watch
2029 (1)
July 2029 (1)
Phase 3Sickle Cell DiseaseRecruiting
Est. primary completion 2029-07-02 · NCT06439082 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 4Sickle Cell DiseaseRecruiting
Est. primary completion 2031-06-10 · NCT04657822 · CT.gov ↗
What to watch

See the full readout calendar ↗